2026-04-14T08:15:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:20.500.12327/29752025-10-22T11:20:31Zcom_2072_4428com_2072_4427col_2072_487898

00925njm 22002777a 4500 dc Marín-Moraleda, David author Muñoz-Basagoiti, Jordana author Tort-Miró, Aida author Navas, María Jesús author Muñoz, Marta author Vidal, Enric author Cobos, Àlex author Martín-Mur, Beatriz author Meas, Sochanwattey author Motuzova, Veronika author Chang, Chia-Yu author Gut, Marta author Accensi, Francesc author Pina-Pedrero, Sonia author Núñez, José Ignacio author Esteve-Codina, Anna author Gavrilov, Boris author Rodriguez, Fernando author Liu, Lihong author Argilaguet, Jordi author 2024-05-09 African swine fever (ASF) is a deadly disease of swine currently causing a worldwide pandemic, leading to severe economic consequences for the porcine industry. The control of disease spread is hampered by the limitation of available effective vaccines. Live attenuated vaccines (LAVs) are currently the most advanced vaccine prototypes, providing strong protection against ASF. However, the significant advances achieved using LAVs must be complemented with further studies to analyze vaccine-induced immunity. Here, we characterized the onset of cross-protective immunity triggered by the LAV candidate BA71ΔCD2. Intranasally vaccinated pigs were challenged with the virulent Georgia 2007/1 strain at days 3, 7 and 12 postvaccination. Only the animals vaccinated 12 days before the challenge had effectively controlled infection progression, showing low virus loads, minor clinical signs and a lack of the unbalanced inflammatory response characteristic of severe disease. Contrarily, the animals vaccinated 3 or 7 days before the challenge just showed a minor delay in disease progression. An analysis of the humoral response and whole blood transcriptome signatures demonstrated that the control of infection was associated with the presence of virusspecific IgG and a cytotoxic response before the challenge. These results contribute to our understanding of protective immunity induced by LAV-based vaccines, encouraging their use in emergency responses in ASF-affected areas. Marín-Moraleda, David, Jordana Muñoz-Basagoiti, Aida Tort-Miró, María Jesús Navas, Marta Muñoz, Enric Vidal, Àlex Cobos, et al. 2024. “Elucidating the Onset of Cross-Protective Immunity after Intranasal Vaccination with the Attenuated African Swine Fever Vaccine Candidate BA71ΔCD2”. Vaccines 12 (5): 517. doi: 10.3390/vaccines12050517 2076-393X http://hdl.handle.net/20.500.12327/2975 https://doi.org/10.3390/vaccines12050517 Elucidating the Onset of Cross-Protective Immunity after Intranasal Vaccination with the Attenuated African Swine Fever Vaccine Candidate BA71ΔCD2